Centromere Protein F () Serves As a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Apr 15

PMID 33854594

Citations 18

Authors

Yugang Huang

Xiuwen Chen

Li Wang

Tieyan Wang

Xianbin Tang

Xiaomin Su

Affiliations

Soon will be listed here.

Abstract

Overexpression of Centromere Protein F () is associated with tumorigenesis of many human malignant tumors. But the molecular mechanism and prognostic value of in patients with hepatocellular carcinoma (HCC) are still unclear. In this essay, expression of in HCC tumors were evaluated in a series of databases, including GEO, TCGA, Oncomine, GEPIA, The Human Protein Atlas and Kaplan-Meier plotter. It was apparent that mRNA and protein expression levels of were significantly increased in patients with HCC and were manifestly associated with the tumor stage of HCC. Aberrant expressions of CENPF were significantly linked with worse overall survival (OS) and progression-free survival (PFS) in HCC patients. Then, immunohistochemistry of in human HCC samples was carried out to suggest that CENPF protein was over-expressed in HCC tissues, compared with paired adjacent non-cancerous samples. And small interfering RNAs of in the human HepG2 cells were further performed to reveal that down-regulation of significantly inhibited cell proliferation, cell migration, and cell invasion, but slightly promoted cell apoptosis in human HepG2 cells. Moreover, the gene-set enrichment analysis (GSEA) was conducted to probe the biology process and molecular signaling pathway of in HCC. The GSEA analysis pointed out that was principally enriched in cell cycle and closely related to and in the regulation of cell cycle, especially during G2/M transition of mitosis in HCC. Additionally, immune infiltration analysis by CIBERSORTx revealed that mutilpe immune cells, including T, etc., were significantly different in HCC samples with CENPF, compared with CENPF. These results collectively demonstrated that might serve as a potential prognostic biomarker and novel therapeutic target for HCC. However, further research is needed to validate our findings and promote the clinical application of in HCC.

Citing Articles

CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways.

Li J, Zhang M, Sun Q, Li X, Du F, Cheng Y Cancer Cell Int. 2025; 25(1):73.

PMID: 40025532 PMC: 11871623. DOI: 10.1186/s12935-025-03700-6.

CENPF as a prognostic marker of glioma: unraveling the molecular mechanisms.

Chen X, Wu Y, Xing Y, Zhong P J Cancer Res Clin Oncol. 2025; 151(2):96.

PMID: 40019588 PMC: 11870995. DOI: 10.1007/s00432-025-06144-7.

Recent updates of centromere proteins in hepatocellular carcinoma: a review.

Yang Z, Chen W, Liu Y, Niu Y Infect Agent Cancer. 2025; 20(1):7.

PMID: 39915786 PMC: 11800463. DOI: 10.1186/s13027-024-00630-2.

Statistical and machine learning based platform-independent key genes identification for hepatocellular carcinoma.

Hasan M, Maniruzzaman M, Huang J, Shin J PLoS One. 2025; 20(2):e0318215.

PMID: 39908244 PMC: 11798446. DOI: 10.1371/journal.pone.0318215.

A Bioinformatics-Based Approach to Discover Novel Biomarkers in Hepatocellular Carcinoma.

Shourideh A, Maddah R, Amiri B, Basharat Z, Shadpirouz M Iran J Public Health. 2024; 53(6):1332-1342.

PMID: 39430152 PMC: 11488550.

References

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Lordick F . Hepatocellular carcinoma-united forces against a global killer. Ann Oncol. 2020; 31(4):449-450. DOI: 10.1016/j.annonc.2020.01.064. View

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

Zong Z, Zou J, Mao R, Ma C, Li N, Wang J . M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling. Front Immunol. 2019; 10:1643. PMC: 6648893. DOI: 10.3389/fimmu.2019.01643. View

Aytes A, Mitrofanova A, Lefebvre C, Alvarez M, Castillo-Martin M, Zheng T . Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014; 25(5):638-651. PMC: 4051317. DOI: 10.1016/j.ccr.2014.03.017. View

Cronin K, Lake A, Scott S, Sherman R, Noone A, Howlader N . Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018; 124(13):2785-2800. PMC: 6033186. DOI: 10.1002/cncr.31551. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M . Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunol Res. 2019; 7(5):737-750. DOI: 10.1158/2326-6066.CIR-18-0436. View

Hause R, Pritchard C, Shendure J, Salipante S . Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016; 22(11):1342-1350. DOI: 10.1038/nm.4191. View

10.

Zhang Z, Lin E, Zhuang H, Xie L, Feng X, Liu J . Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2020; 20:27. PMC: 6986036. DOI: 10.1186/s12935-020-1113-6. View

11.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

12.

Liu G, Li X, Zhang Y . Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int. 2019; 19:22. PMC: 6352338. DOI: 10.1186/s12935-019-0738-9. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

15.

De Toni E, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F . Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut. 2019; 69(1):168-176. PMC: 6943246. DOI: 10.1136/gutjnl-2018-318193. View

16.

Wurmbach E, Chen Y, Khitrov G, Zhang W, Roayaie S, Schwartz M . Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007; 45(4):938-47. DOI: 10.1002/hep.21622. View

17.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

18.

Dai Y, Liu L, Zeng T, Zhu Y, Li J, Chen L . Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013; 436(4):711-8. DOI: 10.1016/j.bbrc.2013.06.021. View

19.

Clijsters L, Hoencamp C, Calis J, Marzio A, Handgraaf S, Cuitino M . Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 2019; 74(6):1264-1277.e7. PMC: 6588466. DOI: 10.1016/j.molcel.2019.04.010. View

20.

Wu F, Li G, Liu H, Zhao Z, Chai R, Liu Y . Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. J Pathol. 2020; 251(3):272-283. DOI: 10.1002/path.5468. View